GlassScriptPhysician profile
Charles Guy Castles, III
NPI 1760587695
$2,022.27
in general payments reported to CMS, 2019-2025
26 companies · $362 in 2025
The $362 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $159 · 2021: $379 · 2022: $196 · 2023: $231 · 2024: $470 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $724.99 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $194.83 | 2019-2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $130.08 | 2019-2022 | |
| Pfizer INC. | $124.88 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $94.69 | 2023-2025 | |
| Aytu Biopharma, INC. | $84.99 | 2020-2025 | Karbinal |
| Glaxosmithkline, LLC. | $76.83 | 2021-2024 | Bexsero, Pediarix |
| Corium, LLC | $68.71 | 2022-2024 | Azstarys |
| Alk-Abello, INC | $58.00 | 2025 | Neffy, Odactra, Grastek |
| Ironshore Pharmaceuticals INC. | $50.70 | 2019 | |
| Mckesson Medical-Surgical, INC. | $50.00 | 2024 | |
| Sanofi Pasteur INC. | $49.02 | 2021-2025 | |
| Verrica Pharmaceuticals INC. | $33.80 | 2023-2024 | Ycanth |
| Seqirus USA INC | $31.64 | 2023-2025 | Flucelvax Quadrivalent, Flucelvax |
| Cranial Technologies, INC | $29.49 | 2024 | Doc Band |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $28.75 | 2019 | |
| Adlon Therapeutics L.P. | $26.93 | 2020-2021 | |
| Shire North American Group INC | $26.02 | 2019 | |
| Mission Pharmacal Company | $25.84 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.95 | 2022 | |
| Genzyme Corporation | $18.98 | 2023 | |
| Ironwood Pharmaceuticals, INC | $17.24 | 2024 | |
| Collegium Pharmaceutical, INC. | $16.23 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $14.83 | 2019 | |
| Neos Therapeutics, LP | $11.95 | 2022 | |
| Genentech USA, INC. | $11.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Castles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.